WAVE Life Sciences (NASDAQ:WVE) Upgraded at Truist Financial

Truist Financial upgraded shares of WAVE Life Sciences (NASDAQ:WVE) to a strong-buy rating in a research note released on Wednesday,Zacks.com reports.

WVE has been the subject of several other reports. B. Riley Financial lifted their price objective on WAVE Life Sciences from $19.00 to $37.00 and gave the company a “buy” rating in a report on Friday, December 12th. Wells Fargo & Company dropped their target price on shares of WAVE Life Sciences from $29.00 to $27.00 and set an “overweight” rating on the stock in a report on Thursday, February 12th. Wall Street Zen downgraded shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Canaccord Genuity Group boosted their price target on shares of WAVE Life Sciences from $43.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Finally, Morgan Stanley set a $28.00 price target on shares of WAVE Life Sciences in a research report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $31.38.

WAVE Life Sciences Stock Up 2.6%

Shares of NASDAQ:WVE opened at $6.36 on Wednesday. WAVE Life Sciences has a 52-week low of $5.02 and a 52-week high of $21.73. The stock has a market cap of $1.20 billion, a P/E ratio of -5.21 and a beta of -1.77. The business’s 50 day moving average is $12.93 and its 200 day moving average is $11.20.

WAVE Life Sciences (NASDAQ:WVE) last issued its earnings results on Thursday, February 26th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The firm had revenue of $17.25 million for the quarter, compared to the consensus estimate of $15.68 million. On average, sell-side analysts anticipate that WAVE Life Sciences will post -1.14 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Kyle Moran sold 3,588 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $48,258.60. Following the sale, the chief financial officer owned 134,385 shares of the company’s stock, valued at $1,807,478.25. This trade represents a 2.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Chandra Vargeese sold 3,228 shares of WAVE Life Sciences stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $43,416.60. Following the completion of the transaction, the insider owned 408,246 shares in the company, valued at $5,490,908.70. This trade represents a 0.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 61,748 shares of company stock valued at $907,809. Company insiders own 23.98% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Hsbc Holdings PLC lifted its position in WAVE Life Sciences by 52.1% during the fourth quarter. Hsbc Holdings PLC now owns 16,990 shares of the company’s stock valued at $291,000 after acquiring an additional 5,823 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in WAVE Life Sciences in the fourth quarter worth $176,000. Virtu Financial LLC purchased a new position in WAVE Life Sciences in the fourth quarter worth $457,000. Invesco Ltd. increased its position in shares of WAVE Life Sciences by 27.5% during the fourth quarter. Invesco Ltd. now owns 179,932 shares of the company’s stock worth $3,059,000 after purchasing an additional 38,806 shares in the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in shares of WAVE Life Sciences during the fourth quarter worth $12,278,000. Institutional investors own 89.73% of the company’s stock.

More WAVE Life Sciences News

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Company press release: management highlighted six‑month, placebo‑adjusted improvements in body composition (240 mg single dose produced ~14% visceral fat reduction, ~5% total fat reduction, +2% lean mass, ~3.3% waist circumference reduction) and continued safety/tolerability — data that supports the therapy’s mechanism and future development plans. Wave press release
• Positive Sentiment: Management commentary / transcripts emphasize the visceral‑fat and body‑composition signal and durability at six months, which supporters point to as a differentiated outcome versus pure body‑weight endpoints. Seeking Alpha transcript
• Positive Sentiment: Analyst positioning remains mixed but includes continued conviction from some firms: Bank of America kept a Buy rating (PT cut), Wells Fargo kept Overweight (PT cut), Truist upgraded to Strong‑Buy and Mizuho issued bullish commentary — these voices can limit downside and attract buyers after the sell‑off. Benzinga (analyst notes)
• Neutral Sentiment: Independent outlets and investor notes characterize the data as “clinically interesting” on body composition but still early‑stage and not yet persuasive on meaningful weight loss — meaning future development and larger trials will determine value. ProactiveInvestors report
• Negative Sentiment: Market reaction: shares plunged >50% after investors focused on the modest ~0.9% body‑weight reduction at six months and the higher‑dose readout that “failed to show a clear improvement” by some measures — the gap between body‑composition signals and headline weight loss disappointed traders. Reuters
• Negative Sentiment: Investor/legal risk: a law firm is publicizing an investigation into potential claims by shareholders, adding litigation overhang and downward pressure on sentiment. GlobeNewswire (Johnson Fistel)
• Negative Sentiment: Analyst downgrades and target cuts followed the update; multiple outlets report steep target cuts and downgrades that reflect lower near‑term expectations and have likely amplified selling pressure. Seeking Alpha downgrade

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.